Parliamentary questions

561. Deputy Donna McGettigan asked the Minister for Health if she considers it acceptable that serious allegations concerning patient safety within CAMHS-ID can remain unaddressed for several months; and the actions she will take to ensure accountability in this case. [35998/26]

562. Deputy Ken O'Flynn asked the Minister for Health the total expenditure by the HSE in each of the years on the reimbursement of medicines prescribed for erectile dysfunction, including sildenafil and tadalafil; medicines prescribed for menopause-related conditions, including hormone replacement therapy products and topical vaginal oestrogen preparations, under the general medical services sche…

563. Deputy Ken O'Flynn asked the Minister for Health if she will confirm whether service provision for early pregnancy loss is standardised across HSE hospital groups; and if she will provide any available comparative information on access to Early Pregnancy Units, diagnostic services, and medical management pathways between hospital groups. [36002/26]

564. Deputy Ken O'Flynn asked the Minister for Health the clinical pathways in place in each HSE maternity hospital and hospital group for the management of early pregnancy loss; whether medical management using pharmacological treatment including Misoprostol is available within each hospital group; and if she will provide a breakdown of the models of care in operation (including expectant, medica…

565. Deputy Ken O'Flynn asked the Minister for Health the number and location of early pregnancy units or equivalent dedicated early pregnancy assessment services within the HSE maternity hospital system in each of the past five years, if she will outline any hospitals without access to a dedicated early pregnancy assessment service; and if she will make a statement on the matter. [36004/26]

566. Deputy Ken O'Flynn asked the Minister for Health the number of recorded cases of early pregnancy loss managed within HSE maternity hospitals ; and the number of cases managed by expectant management, medical management including pharmacological treatment such as Misoprostol, and surgical intervention; and if she will provide a breakdown by hospital group, in each of the years 2021 to 2025 and…

567. Deputy Ken O'Flynn asked the Minister for Health whether any monetary approval thresholds exist within the treatment abroad scheme requiring additional sign-off for high-cost procedures; the officials or grades responsible for such approvals; and if she will provide the thresholds currently applied. [36018/26]

568. Deputy Ken O'Flynn asked the Minister for Health whether the treatment abroad scheme operates any formal value-for-money assessment process prior to approving exceptionally high-cost procedures abroad; and if so, the methodology used. [36019/26]

569. Deputy Ken O'Flynn asked the Minister for Health the number of Treatment Abroad Scheme applications approved with an estimated cost exceeding in each year since 2020 (details supplied). [36020/26]

570. Deputy Ken O'Flynn asked the Minister for Health whether any applications under the Treatment Abroad Scheme have been refused wholly or partly on financial, budgetary, or proportionality grounds since 2020; and if she will provide annual figures. [36021/26]

571. Deputy Ken O'Flynn asked the Minister for Health whether the HSE maintains a central register of high-cost overseas procedures approved under the Treatment Abroad Scheme; and if so, the governance and reporting arrangements applying to that register. [36022/26]

572. Deputy Ken O'Flynn asked the Minister for Health the dates of all internal audit reviews, Comptroller and Auditor General examinations, or other formal oversight reviews conducted in respect of the Treatment Abroad Scheme since 2020; and if copies of findings or recommendations will be provided. [36023/26]

573. Deputy Ken O'Flynn asked the Minister for Health whether any risk assessment has been conducted regarding financial exposure arising from exceptionally high-cost procedures funded under the Treatment Abroad Scheme; and if so, whether she will provide details. [36024/26]

574. Deputy Ken O'Flynn asked the Minister for Health whether the Treatment Abroad Scheme has any specific governance pathway for novel, experimental, or highly specialised procedures abroad involving significant State expenditure. [36025/26]

575. Deputy Ken O'Flynn asked the Minister for Health whether the Treatment Abroad Scheme maintains procedure-specific coding or categorisation for any surgical specialties funded abroad; and if so, to provide the categories recorded. [36026/26]

576. Deputy Ken O'Flynn asked the Minister for Health whether the HSE is capable of identifying retrospectively the categories of gender affirmation procedures funded under the Treatment Abroad Scheme through MDT reports, referral documentation, consultant submissions, or reimbursement records. [36027/26]

577. Deputy Ken O'Flynn asked the Minister for Health whether any legal, GDPR, administrative, or policy barrier prevents the Treatment Abroad Scheme from recording anonymised procedure-category data for overseas gender-related surgeries. [36028/26]

578. Deputy Ken O'Flynn asked the Minister for Health whether the Internal Audit Office of the HSE or the Comptroller and Auditor General has ever examined governance, expenditure tracking, safeguarding, or procedure categorisation relating to overseas gender affirmation surgery referrals under the Treatment Abroad Scheme. [36029/26]

579. Deputy Ken O'Flynn asked the Minister for Health whether her Department has requested the introduction of structured reporting or coding mechanisms relating to gender affirmation procedures funded abroad under the Treatment Abroad Scheme. [36030/26]

580. Deputy Ken O'Flynn asked the Minister for Health the total annual expenditure under the Treatment Abroad Scheme on overseas gender-related surgical referrals for each year from 2020 to date. [36031/26]

581. Deputy Ken O'Flynn asked the Minister for Health whether the Treatment Abroad Scheme records the age profile of persons approved for overseas gender affirmation surgeries. [36032/26]

582. Deputy Ken O'Flynn asked the Minister for Health whether the HSE maintains any national dataset recording the number of referrals to Suicide Crisis Assessment Nurse services that are rejected, redirected, or deemed ineligible for assessment; and if not, whether she intends to introduce such reporting arrangements. [36043/26]

583. Deputy Ken O'Flynn asked the Minister for Health whether the HSE has conducted any governance review, clinical risk assessment, or audit regarding the absence of national data collection on rejected or redirected referrals within the Suicide Crisis Assessment Nurse pathway since its implementation. [36044/26]

584. Deputy Ken O'Flynn asked the Minister for Health whether the HSE tracks outcomes for persons who are referred to Suicide Crisis Assessment Nurse services but are subsequently deemed ineligible or redirected to alternative pathways; and if not, the reason such outcome monitoring is not maintained. [36045/26]

585. Deputy Ken O'Flynn asked the Minister for Health whether the HSE tracks outcomes for persons who are referred to Suicide Crisis Assessment Nurse services but are subsequently deemed ineligible or redirected to alternative pathways; and if not, the reason such outcome monitoring is not maintained. [36046/26]